Page 111 - Mployee Wellness Programs News Today

The Senate Finance Committee voted 26-1 to advance the Modernizing and Ensuring PBM Accountability Act. The bill has several provisions, including delinking PBM income from prescription drug prices under Medicare Part D and banning spread pricing in Medicaid.

To maximize the digital clinical trial opportunity, it is imperative to establish a solid foundation of data collection and management best practices and capitalize on the advancements in data management technologies.

I invite insurance companies to engage in meaningful dialogue with urgent care providers to understand the challenges they face and explore fair reimbursement models that reflect the value they bring to patients.

UpLift's Series A funding round was led by Ballast Point Ventures and included participation from Kapor Capital, Front Porch Ventures and B Capital. In total, UpLift has raised more than $22 million.

A new proposed rule by the Biden-Harris Administration would require health plans to improve their analyses of their mental health benefits and make clear that they cannot engage in practices that make it more difficult for members to access mental health support compared to physical health.

Pear Therapeutics was once regarded as a digital therapeutics pioneer, but its spiral into bankruptcy has the industry searching for the best path forward. While some favor going direct to consumers, others say the solution is in generating more robust clinical trial data to persuade hesitant payers.

The webinar, sponsored by Intelligent Medical Objects, will explore the impact of poor data quality and methods to improve patient data quality. It will also highlight healthcare industry employee burnout and how to improve retention.

Octave Bioscience, based in Menlo Park, California, just closed a $30 million extension to its Series B funding round.

Social media should play a bigger part in public health crisis planning, according to a recent analysis. The analysis explored the crucial role that Twitter and other social media platforms played when the app for Abbott’s FreeStyle Libre system crashed earlier this month in the U.K.

In 2020, 46.9% of all novel drugs approved by the FDA were for rare diseases, as compared to 23.5% in 2012. Investment is expected to continue trending upward, with estimates suggesting that global spending on rare disease therapies will reach $260 billion by the end of 2025.